BriaCell Therapeutics Corp. (TSE:BCT – Free Report) – Analysts at HC Wainwright boosted their FY2024 earnings per share estimates for shares of BriaCell Therapeutics in a research report issued to clients and investors on Thursday, September 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($1.09) for the year, up from their previous estimate of ($1.90). HC Wainwright also issued estimates for BriaCell Therapeutics’ Q4 2024 earnings at ($0.71) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at ($0.33) EPS, FY2027 earnings at ($0.26) EPS and FY2028 earnings at ($0.16) EPS.
BriaCell Therapeutics Price Performance
TSE:BCT opened at C$0.88 on Monday. The business’s 50-day simple moving average is C$0.95 and its 200-day simple moving average is C$2.05. BriaCell Therapeutics has a fifty-two week low of C$0.64 and a fifty-two week high of C$8.65. The stock has a market capitalization of C$27.02 million, a PE ratio of -1.76 and a beta of 1.74.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- What Are Dividend Champions? How to Invest in the Champions
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Use Stock Screeners to Find Stocks
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.